Oracle Alpha’s PTC Therapeutics PTCT Stock Holding History

Oracle Alpha’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$546K	Buy	18,755 +6,546	+54%	+$183K	0.98%	11
2023 Q4	$336K	Buy	+12,209	New	+$279K	0.44%	83

Other funds holding PTCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Oracle Alpha's PTCT Position: Q1 2024 in Review

Oracle Alpha increased its PTC Therapeutics (PTCT) stake by 54% in Q1 2024, buying an estimated $183K and bringing the position to 18,755 shares worth $546K. The position accounts for 0.98% of the portfolio, ranked #11.

Oracle Alpha first reported a position in PTCT in Q4 2023 and has held it in 2 quarters since. 184 funds tracked by Wall St. Rank hold PTCT as of Q1 2024.

Oracle Alpha held 18,755 shares of PTC Therapeutics worth $546K as of Q1 2024.
Oracle Alpha bought 6,546 PTC Therapeutics shares in Q1 2024, an estimated $183K.
PTC Therapeutics made up 0.98% of Oracle Alpha's portfolio in Q1 2024, its #11 holding.
Oracle Alpha first reported a position in PTC Therapeutics in Q4 2023 and has held it in 2 quarters since.
184 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2024.

Based on Oracle Alpha's 13F filing for Q1 2024, filed 15 May 2024.